Guarimata, J. D., & Lavecchia, M. (2024). In Silico Study of FDA-Approved Drugs on <i>Leishmania infantum</i> CYP51, a Drug Repositioning Approach in Visceral Leishmaniasis. MDPI AG.
Chicago Style (17th ed.) CitationGuarimata, Juan Diego, and Martin Lavecchia. In Silico Study of FDA-Approved Drugs on <i>Leishmania Infantum</i> CYP51, a Drug Repositioning Approach in Visceral Leishmaniasis. MDPI AG, 2024.
MLA (9th ed.) CitationGuarimata, Juan Diego, and Martin Lavecchia. In Silico Study of FDA-Approved Drugs on <i>Leishmania Infantum</i> CYP51, a Drug Repositioning Approach in Visceral Leishmaniasis. MDPI AG, 2024.
Warning: These citations may not always be 100% accurate.